Immunogenicity of a half-dose of adjuvanted 2009 pandemic H1N1 influenza vaccine in adults: a prospective cohort study
Identifieur interne : 001738 ( PascalFrancis/Curation ); précédent : 001737; suivant : 001739Immunogenicity of a half-dose of adjuvanted 2009 pandemic H1N1 influenza vaccine in adults: a prospective cohort study
Auteurs : B. L. Coleman [Canada] ; S. P. Kuster [Canada] ; J. Gubbay [Canada] ; D. Scheifele [Canada] ; Y. Li [Canada] ; D. Low [Canada] ; N. Crowcroft [Canada] ; T. Mazzulli [Canada] ; L. Shi [Canada] ; S. A. Halperin [Canada] ; B. Law [Canada] ; A. Mcgeer [Canada]Source :
- European journal of clinical microbiology & infectious diseases : (Print) [ 0934-9723 ] ; 2012.
Descripteurs français
- Pascal (Inist)
- Wicri :
English descriptors
- KwdEn :
Abstract
We aimed to assess the immunogenicity of a single half-dose of AS03-adjuvanted monovalent 2009 pandemic H1N1 vaccine in healthy adults. Healthy subjects age 20-60 years were prospectively enrolled in a cohort receiving intramuscular administration of a single half-dose (1.875 μg of hemagglutinin [HA]) of adjuvanted 2009 pandemic H1N1 influenza vaccine. Data from participants enrolled in a concomitant study of immunogenicity following a full-dose (3.75 μg of HA) are presented concurrently. Sera for assessment of hemagglutination-inhibiting (HAI) antibody to the vaccine strain were obtained before and 14 or 21 days after vaccination. Ninety-seven participants received a half-dose and 50 received a full-dose of vaccine. In the half-dose cohort, Food and Drug Administration criteria for immunogenicity regarding seroprotection and seroconversion rates were met for subjects aged 20-45 years, but not for those aged 46-60 years. There was no statistically significant difference in the proportion of individuals achieving a post-vaccination HAI titre of ≥1:40, the geometric mean titres of post-vaccination antibody, or the proportion of individuals with a four-fold or greater increase in antibody levels between the two cohorts. Participants 46-60 years of age were significantly less likely to be seroprotected at day 21 than those 20-45 years old in both cohorts. Immunogenicity of a half dose of adjuvanted pH1N1 influenza vaccine was adequate in subjects aged 20-45 years. Dose reduction is a possible strategy for expanding the availability in the event of vaccine shortage in this age group.
| pA |
|
|---|
Links toward previous steps (curation, corpus...)
- to stream PascalFrancis, to step Corpus: Pour aller vers cette notice dans l'étape Curation :000698
Links to Exploration step
Pascal:12-0182435Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Immunogenicity of a half-dose of adjuvanted 2009 pandemic H1N1 influenza vaccine in adults: a prospective cohort study</title><author><name sortKey="Coleman, B L" sort="Coleman, B L" uniqKey="Coleman B" first="B. L." last="Coleman">B. L. Coleman</name><affiliation wicri:level="1"><inist:fA14 i1="02"><s1>University of Toronto</s1><s2>Toronto, Ontario</s2><s3>CAN</s3><sZ>1 aut.</sZ><sZ>3 aut.</sZ><sZ>6 aut.</sZ><sZ>7 aut.</sZ></inist:fA14><country>Canada</country></affiliation></author><author><name sortKey="Kuster, S P" sort="Kuster, S P" uniqKey="Kuster S" first="S. P." last="Kuster">S. P. Kuster</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Microbiology, Mount Sinai Hospital, 600 University Ave, Room 210</s1><s2>Toronto, Ontario M5G 1X5</s2><s3>CAN</s3><sZ>2 aut.</sZ><sZ>6 aut.</sZ><sZ>8 aut.</sZ><sZ>12 aut.</sZ></inist:fA14><country>Canada</country></affiliation></author><author><name sortKey="Gubbay, J" sort="Gubbay, J" uniqKey="Gubbay J" first="J." last="Gubbay">J. Gubbay</name><affiliation wicri:level="1"><inist:fA14 i1="02"><s1>University of Toronto</s1><s2>Toronto, Ontario</s2><s3>CAN</s3><sZ>1 aut.</sZ><sZ>3 aut.</sZ><sZ>6 aut.</sZ><sZ>7 aut.</sZ></inist:fA14><country>Canada</country></affiliation><affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Ontario Agency of Health Promotion & Protection</s1><s2>Toronto, Ontario</s2><s3>CAN</s3><sZ>3 aut.</sZ><sZ>6 aut.</sZ><sZ>7 aut.</sZ><sZ>9 aut.</sZ></inist:fA14><country>Canada</country></affiliation></author><author><name sortKey="Scheifele, D" sort="Scheifele, D" uniqKey="Scheifele D" first="D." last="Scheifele">D. Scheifele</name><affiliation wicri:level="1"><inist:fA14 i1="04"><s1>University of British Columbia</s1><s2>Vancouver, British Columbia</s2><s3>CAN</s3><sZ>4 aut.</sZ></inist:fA14><country>Canada</country></affiliation><affiliation wicri:level="1"><inist:fA14 i1="05"><s1>Child & Family Research Institute</s1><s2>Vancouver, British Columbia</s2><s3>CAN</s3><sZ>4 aut.</sZ></inist:fA14><country>Canada</country></affiliation><affiliation wicri:level="1"><inist:fA14 i1="09"><s1>Public Health Agency of Canada-Canadian Institutes of Health Research Influenza Research Network</s1><s2>Ottawa, Ontario</s2><s3>CAN</s3><sZ>4 aut.</sZ><sZ>10 aut.</sZ><sZ>11 aut.</sZ><sZ>12 aut.</sZ></inist:fA14><country>Canada</country></affiliation></author><author><name sortKey="Li, Y" sort="Li, Y" uniqKey="Li Y" first="Y." last="Li">Y. Li</name><affiliation wicri:level="1"><inist:fA14 i1="06"><s1>National Microbiology Laboratory</s1><s2>Winnipeg, Mannitoba</s2><s3>CAN</s3><sZ>5 aut.</sZ></inist:fA14><country>Canada</country></affiliation></author><author><name sortKey="Low, D" sort="Low, D" uniqKey="Low D" first="D." last="Low">D. Low</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Microbiology, Mount Sinai Hospital, 600 University Ave, Room 210</s1><s2>Toronto, Ontario M5G 1X5</s2><s3>CAN</s3><sZ>2 aut.</sZ><sZ>6 aut.</sZ><sZ>8 aut.</sZ><sZ>12 aut.</sZ></inist:fA14><country>Canada</country></affiliation><affiliation wicri:level="1"><inist:fA14 i1="02"><s1>University of Toronto</s1><s2>Toronto, Ontario</s2><s3>CAN</s3><sZ>1 aut.</sZ><sZ>3 aut.</sZ><sZ>6 aut.</sZ><sZ>7 aut.</sZ></inist:fA14><country>Canada</country></affiliation><affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Ontario Agency of Health Promotion & Protection</s1><s2>Toronto, Ontario</s2><s3>CAN</s3><sZ>3 aut.</sZ><sZ>6 aut.</sZ><sZ>7 aut.</sZ><sZ>9 aut.</sZ></inist:fA14><country>Canada</country></affiliation></author><author><name sortKey="Crowcroft, N" sort="Crowcroft, N" uniqKey="Crowcroft N" first="N." last="Crowcroft">N. Crowcroft</name><affiliation wicri:level="1"><inist:fA14 i1="02"><s1>University of Toronto</s1><s2>Toronto, Ontario</s2><s3>CAN</s3><sZ>1 aut.</sZ><sZ>3 aut.</sZ><sZ>6 aut.</sZ><sZ>7 aut.</sZ></inist:fA14><country>Canada</country></affiliation><affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Ontario Agency of Health Promotion & Protection</s1><s2>Toronto, Ontario</s2><s3>CAN</s3><sZ>3 aut.</sZ><sZ>6 aut.</sZ><sZ>7 aut.</sZ><sZ>9 aut.</sZ></inist:fA14><country>Canada</country></affiliation></author><author><name sortKey="Mazzulli, T" sort="Mazzulli, T" uniqKey="Mazzulli T" first="T." last="Mazzulli">T. Mazzulli</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Microbiology, Mount Sinai Hospital, 600 University Ave, Room 210</s1><s2>Toronto, Ontario M5G 1X5</s2><s3>CAN</s3><sZ>2 aut.</sZ><sZ>6 aut.</sZ><sZ>8 aut.</sZ><sZ>12 aut.</sZ></inist:fA14><country>Canada</country></affiliation></author><author><name sortKey="Shi, L" sort="Shi, L" uniqKey="Shi L" first="L." last="Shi">L. Shi</name><affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Ontario Agency of Health Promotion & Protection</s1><s2>Toronto, Ontario</s2><s3>CAN</s3><sZ>3 aut.</sZ><sZ>6 aut.</sZ><sZ>7 aut.</sZ><sZ>9 aut.</sZ></inist:fA14><country>Canada</country></affiliation></author><author><name sortKey="Halperin, S A" sort="Halperin, S A" uniqKey="Halperin S" first="S. A." last="Halperin">S. A. Halperin</name><affiliation wicri:level="1"><inist:fA14 i1="07"><s1>Canadian Center for Vaccinology</s1><s2>Halifax, Nova Scotia</s2><s3>CAN</s3><sZ>10 aut.</sZ></inist:fA14><country>Canada</country></affiliation><affiliation wicri:level="1"><inist:fA14 i1="09"><s1>Public Health Agency of Canada-Canadian Institutes of Health Research Influenza Research Network</s1><s2>Ottawa, Ontario</s2><s3>CAN</s3><sZ>4 aut.</sZ><sZ>10 aut.</sZ><sZ>11 aut.</sZ><sZ>12 aut.</sZ></inist:fA14><country>Canada</country></affiliation></author><author><name sortKey="Law, B" sort="Law, B" uniqKey="Law B" first="B." last="Law">B. Law</name><affiliation wicri:level="1"><inist:fA14 i1="08"><s1>Public Health Agency of Canada</s1><s2>Ottawa, Ontario</s2><s3>CAN</s3><sZ>11 aut.</sZ></inist:fA14><country>Canada</country></affiliation><affiliation wicri:level="1"><inist:fA14 i1="09"><s1>Public Health Agency of Canada-Canadian Institutes of Health Research Influenza Research Network</s1><s2>Ottawa, Ontario</s2><s3>CAN</s3><sZ>4 aut.</sZ><sZ>10 aut.</sZ><sZ>11 aut.</sZ><sZ>12 aut.</sZ></inist:fA14><country>Canada</country></affiliation></author><author><name sortKey="Mcgeer, A" sort="Mcgeer, A" uniqKey="Mcgeer A" first="A." last="Mcgeer">A. Mcgeer</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Microbiology, Mount Sinai Hospital, 600 University Ave, Room 210</s1><s2>Toronto, Ontario M5G 1X5</s2><s3>CAN</s3><sZ>2 aut.</sZ><sZ>6 aut.</sZ><sZ>8 aut.</sZ><sZ>12 aut.</sZ></inist:fA14><country>Canada</country></affiliation><affiliation wicri:level="1"><inist:fA14 i1="09"><s1>Public Health Agency of Canada-Canadian Institutes of Health Research Influenza Research Network</s1><s2>Ottawa, Ontario</s2><s3>CAN</s3><sZ>4 aut.</sZ><sZ>10 aut.</sZ><sZ>11 aut.</sZ><sZ>12 aut.</sZ></inist:fA14><country>Canada</country></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">INIST</idno><idno type="inist">12-0182435</idno><date when="2012">2012</date><idno type="stanalyst">PASCAL 12-0182435 INIST</idno><idno type="RBID">Pascal:12-0182435</idno><idno type="wicri:Area/PascalFrancis/Corpus">000698</idno><idno type="wicri:Area/PascalFrancis/Curation">001738</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Immunogenicity of a half-dose of adjuvanted 2009 pandemic H1N1 influenza vaccine in adults: a prospective cohort study</title><author><name sortKey="Coleman, B L" sort="Coleman, B L" uniqKey="Coleman B" first="B. L." last="Coleman">B. L. Coleman</name><affiliation wicri:level="1"><inist:fA14 i1="02"><s1>University of Toronto</s1><s2>Toronto, Ontario</s2><s3>CAN</s3><sZ>1 aut.</sZ><sZ>3 aut.</sZ><sZ>6 aut.</sZ><sZ>7 aut.</sZ></inist:fA14><country>Canada</country></affiliation></author><author><name sortKey="Kuster, S P" sort="Kuster, S P" uniqKey="Kuster S" first="S. P." last="Kuster">S. P. Kuster</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Microbiology, Mount Sinai Hospital, 600 University Ave, Room 210</s1><s2>Toronto, Ontario M5G 1X5</s2><s3>CAN</s3><sZ>2 aut.</sZ><sZ>6 aut.</sZ><sZ>8 aut.</sZ><sZ>12 aut.</sZ></inist:fA14><country>Canada</country></affiliation></author><author><name sortKey="Gubbay, J" sort="Gubbay, J" uniqKey="Gubbay J" first="J." last="Gubbay">J. Gubbay</name><affiliation wicri:level="1"><inist:fA14 i1="02"><s1>University of Toronto</s1><s2>Toronto, Ontario</s2><s3>CAN</s3><sZ>1 aut.</sZ><sZ>3 aut.</sZ><sZ>6 aut.</sZ><sZ>7 aut.</sZ></inist:fA14><country>Canada</country></affiliation><affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Ontario Agency of Health Promotion & Protection</s1><s2>Toronto, Ontario</s2><s3>CAN</s3><sZ>3 aut.</sZ><sZ>6 aut.</sZ><sZ>7 aut.</sZ><sZ>9 aut.</sZ></inist:fA14><country>Canada</country></affiliation></author><author><name sortKey="Scheifele, D" sort="Scheifele, D" uniqKey="Scheifele D" first="D." last="Scheifele">D. Scheifele</name><affiliation wicri:level="1"><inist:fA14 i1="04"><s1>University of British Columbia</s1><s2>Vancouver, British Columbia</s2><s3>CAN</s3><sZ>4 aut.</sZ></inist:fA14><country>Canada</country></affiliation><affiliation wicri:level="1"><inist:fA14 i1="05"><s1>Child & Family Research Institute</s1><s2>Vancouver, British Columbia</s2><s3>CAN</s3><sZ>4 aut.</sZ></inist:fA14><country>Canada</country></affiliation><affiliation wicri:level="1"><inist:fA14 i1="09"><s1>Public Health Agency of Canada-Canadian Institutes of Health Research Influenza Research Network</s1><s2>Ottawa, Ontario</s2><s3>CAN</s3><sZ>4 aut.</sZ><sZ>10 aut.</sZ><sZ>11 aut.</sZ><sZ>12 aut.</sZ></inist:fA14><country>Canada</country></affiliation></author><author><name sortKey="Li, Y" sort="Li, Y" uniqKey="Li Y" first="Y." last="Li">Y. Li</name><affiliation wicri:level="1"><inist:fA14 i1="06"><s1>National Microbiology Laboratory</s1><s2>Winnipeg, Mannitoba</s2><s3>CAN</s3><sZ>5 aut.</sZ></inist:fA14><country>Canada</country></affiliation></author><author><name sortKey="Low, D" sort="Low, D" uniqKey="Low D" first="D." last="Low">D. Low</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Microbiology, Mount Sinai Hospital, 600 University Ave, Room 210</s1><s2>Toronto, Ontario M5G 1X5</s2><s3>CAN</s3><sZ>2 aut.</sZ><sZ>6 aut.</sZ><sZ>8 aut.</sZ><sZ>12 aut.</sZ></inist:fA14><country>Canada</country></affiliation><affiliation wicri:level="1"><inist:fA14 i1="02"><s1>University of Toronto</s1><s2>Toronto, Ontario</s2><s3>CAN</s3><sZ>1 aut.</sZ><sZ>3 aut.</sZ><sZ>6 aut.</sZ><sZ>7 aut.</sZ></inist:fA14><country>Canada</country></affiliation><affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Ontario Agency of Health Promotion & Protection</s1><s2>Toronto, Ontario</s2><s3>CAN</s3><sZ>3 aut.</sZ><sZ>6 aut.</sZ><sZ>7 aut.</sZ><sZ>9 aut.</sZ></inist:fA14><country>Canada</country></affiliation></author><author><name sortKey="Crowcroft, N" sort="Crowcroft, N" uniqKey="Crowcroft N" first="N." last="Crowcroft">N. Crowcroft</name><affiliation wicri:level="1"><inist:fA14 i1="02"><s1>University of Toronto</s1><s2>Toronto, Ontario</s2><s3>CAN</s3><sZ>1 aut.</sZ><sZ>3 aut.</sZ><sZ>6 aut.</sZ><sZ>7 aut.</sZ></inist:fA14><country>Canada</country></affiliation><affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Ontario Agency of Health Promotion & Protection</s1><s2>Toronto, Ontario</s2><s3>CAN</s3><sZ>3 aut.</sZ><sZ>6 aut.</sZ><sZ>7 aut.</sZ><sZ>9 aut.</sZ></inist:fA14><country>Canada</country></affiliation></author><author><name sortKey="Mazzulli, T" sort="Mazzulli, T" uniqKey="Mazzulli T" first="T." last="Mazzulli">T. Mazzulli</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Microbiology, Mount Sinai Hospital, 600 University Ave, Room 210</s1><s2>Toronto, Ontario M5G 1X5</s2><s3>CAN</s3><sZ>2 aut.</sZ><sZ>6 aut.</sZ><sZ>8 aut.</sZ><sZ>12 aut.</sZ></inist:fA14><country>Canada</country></affiliation></author><author><name sortKey="Shi, L" sort="Shi, L" uniqKey="Shi L" first="L." last="Shi">L. Shi</name><affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Ontario Agency of Health Promotion & Protection</s1><s2>Toronto, Ontario</s2><s3>CAN</s3><sZ>3 aut.</sZ><sZ>6 aut.</sZ><sZ>7 aut.</sZ><sZ>9 aut.</sZ></inist:fA14><country>Canada</country></affiliation></author><author><name sortKey="Halperin, S A" sort="Halperin, S A" uniqKey="Halperin S" first="S. A." last="Halperin">S. A. Halperin</name><affiliation wicri:level="1"><inist:fA14 i1="07"><s1>Canadian Center for Vaccinology</s1><s2>Halifax, Nova Scotia</s2><s3>CAN</s3><sZ>10 aut.</sZ></inist:fA14><country>Canada</country></affiliation><affiliation wicri:level="1"><inist:fA14 i1="09"><s1>Public Health Agency of Canada-Canadian Institutes of Health Research Influenza Research Network</s1><s2>Ottawa, Ontario</s2><s3>CAN</s3><sZ>4 aut.</sZ><sZ>10 aut.</sZ><sZ>11 aut.</sZ><sZ>12 aut.</sZ></inist:fA14><country>Canada</country></affiliation></author><author><name sortKey="Law, B" sort="Law, B" uniqKey="Law B" first="B." last="Law">B. Law</name><affiliation wicri:level="1"><inist:fA14 i1="08"><s1>Public Health Agency of Canada</s1><s2>Ottawa, Ontario</s2><s3>CAN</s3><sZ>11 aut.</sZ></inist:fA14><country>Canada</country></affiliation><affiliation wicri:level="1"><inist:fA14 i1="09"><s1>Public Health Agency of Canada-Canadian Institutes of Health Research Influenza Research Network</s1><s2>Ottawa, Ontario</s2><s3>CAN</s3><sZ>4 aut.</sZ><sZ>10 aut.</sZ><sZ>11 aut.</sZ><sZ>12 aut.</sZ></inist:fA14><country>Canada</country></affiliation></author><author><name sortKey="Mcgeer, A" sort="Mcgeer, A" uniqKey="Mcgeer A" first="A." last="Mcgeer">A. Mcgeer</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Microbiology, Mount Sinai Hospital, 600 University Ave, Room 210</s1><s2>Toronto, Ontario M5G 1X5</s2><s3>CAN</s3><sZ>2 aut.</sZ><sZ>6 aut.</sZ><sZ>8 aut.</sZ><sZ>12 aut.</sZ></inist:fA14><country>Canada</country></affiliation><affiliation wicri:level="1"><inist:fA14 i1="09"><s1>Public Health Agency of Canada-Canadian Institutes of Health Research Influenza Research Network</s1><s2>Ottawa, Ontario</s2><s3>CAN</s3><sZ>4 aut.</sZ><sZ>10 aut.</sZ><sZ>11 aut.</sZ><sZ>12 aut.</sZ></inist:fA14><country>Canada</country></affiliation></author></analytic><series><title level="j" type="main">European journal of clinical microbiology & infectious diseases : (Print)</title><title level="j" type="abbreviated">Eur. j. clin. microbiol. infect. dis. : (Print)</title><idno type="ISSN">0934-9723</idno><imprint><date when="2012">2012</date></imprint></series></biblStruct></sourceDesc><seriesStmt><title level="j" type="main">European journal of clinical microbiology & infectious diseases : (Print)</title><title level="j" type="abbreviated">Eur. j. clin. microbiol. infect. dis. : (Print)</title><idno type="ISSN">0934-9723</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult</term><term>Cohort study</term><term>Dose</term><term>H1N1 influenza</term><term>Immunogenicity</term><term>Immunoprophylaxis</term><term>Influenza A</term><term>Microbiology</term><term>Prevention</term><term>Vaccine</term></keywords><keywords scheme="Pascal" xml:lang="fr"><term>Grippe A</term><term>Immunoprophylaxie</term><term>Immunogénicité</term><term>Dose</term><term>Prévention</term><term>Vaccin</term><term>Adulte</term><term>Etude cohorte</term><term>Microbiologie</term><term>Grippe H1N1</term></keywords><keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Vaccin</term><term>Adulte</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">We aimed to assess the immunogenicity of a single half-dose of AS03-adjuvanted monovalent 2009 pandemic H1N1 vaccine in healthy adults. Healthy subjects age 20-60 years were prospectively enrolled in a cohort receiving intramuscular administration of a single half-dose (1.875 μg of hemagglutinin [HA]) of adjuvanted 2009 pandemic H1N1 influenza vaccine. Data from participants enrolled in a concomitant study of immunogenicity following a full-dose (3.75 μg of HA) are presented concurrently. Sera for assessment of hemagglutination-inhibiting (HAI) antibody to the vaccine strain were obtained before and 14 or 21 days after vaccination. Ninety-seven participants received a half-dose and 50 received a full-dose of vaccine. In the half-dose cohort, Food and Drug Administration criteria for immunogenicity regarding seroprotection and seroconversion rates were met for subjects aged 20-45 years, but not for those aged 46-60 years. There was no statistically significant difference in the proportion of individuals achieving a post-vaccination HAI titre of ≥1:40, the geometric mean titres of post-vaccination antibody, or the proportion of individuals with a four-fold or greater increase in antibody levels between the two cohorts. Participants 46-60 years of age were significantly less likely to be seroprotected at day 21 than those 20-45 years old in both cohorts. Immunogenicity of a half dose of adjuvanted pH1N1 influenza vaccine was adequate in subjects aged 20-45 years. Dose reduction is a possible strategy for expanding the availability in the event of vaccine shortage in this age group.</div></front></TEI><inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0934-9723</s0></fA01><fA03 i2="1"><s0>Eur. j. clin. microbiol. infect. dis. : (Print)</s0></fA03><fA05><s2>31</s2></fA05><fA06><s2>4</s2></fA06><fA08 i1="01" i2="1" l="ENG"><s1>Immunogenicity of a half-dose of adjuvanted 2009 pandemic H1N1 influenza vaccine in adults: a prospective cohort study</s1></fA08><fA11 i1="01" i2="1"><s1>COLEMAN (B. L.)</s1></fA11><fA11 i1="02" i2="1"><s1>KUSTER (S. P.)</s1></fA11><fA11 i1="03" i2="1"><s1>GUBBAY (J.)</s1></fA11><fA11 i1="04" i2="1"><s1>SCHEIFELE (D.)</s1></fA11><fA11 i1="05" i2="1"><s1>LI (Y.)</s1></fA11><fA11 i1="06" i2="1"><s1>LOW (D.)</s1></fA11><fA11 i1="07" i2="1"><s1>CROWCROFT (N.)</s1></fA11><fA11 i1="08" i2="1"><s1>MAZZULLI (T.)</s1></fA11><fA11 i1="09" i2="1"><s1>SHI (L.)</s1></fA11><fA11 i1="10" i2="1"><s1>HALPERIN (S. A.)</s1></fA11><fA11 i1="11" i2="1"><s1>LAW (B.)</s1></fA11><fA11 i1="12" i2="1"><s1>MCGEER (A.)</s1></fA11><fA14 i1="01"><s1>Department of Microbiology, Mount Sinai Hospital, 600 University Ave, Room 210</s1><s2>Toronto, Ontario M5G 1X5</s2><s3>CAN</s3><sZ>2 aut.</sZ><sZ>6 aut.</sZ><sZ>8 aut.</sZ><sZ>12 aut.</sZ></fA14><fA14 i1="02"><s1>University of Toronto</s1><s2>Toronto, Ontario</s2><s3>CAN</s3><sZ>1 aut.</sZ><sZ>3 aut.</sZ><sZ>6 aut.</sZ><sZ>7 aut.</sZ></fA14><fA14 i1="03"><s1>Ontario Agency of Health Promotion & Protection</s1><s2>Toronto, Ontario</s2><s3>CAN</s3><sZ>3 aut.</sZ><sZ>6 aut.</sZ><sZ>7 aut.</sZ><sZ>9 aut.</sZ></fA14><fA14 i1="04"><s1>University of British Columbia</s1><s2>Vancouver, British Columbia</s2><s3>CAN</s3><sZ>4 aut.</sZ></fA14><fA14 i1="05"><s1>Child & Family Research Institute</s1><s2>Vancouver, British Columbia</s2><s3>CAN</s3><sZ>4 aut.</sZ></fA14><fA14 i1="06"><s1>National Microbiology Laboratory</s1><s2>Winnipeg, Mannitoba</s2><s3>CAN</s3><sZ>5 aut.</sZ></fA14><fA14 i1="07"><s1>Canadian Center for Vaccinology</s1><s2>Halifax, Nova Scotia</s2><s3>CAN</s3><sZ>10 aut.</sZ></fA14><fA14 i1="08"><s1>Public Health Agency of Canada</s1><s2>Ottawa, Ontario</s2><s3>CAN</s3><sZ>11 aut.</sZ></fA14><fA14 i1="09"><s1>Public Health Agency of Canada-Canadian Institutes of Health Research Influenza Research Network</s1><s2>Ottawa, Ontario</s2><s3>CAN</s3><sZ>4 aut.</sZ><sZ>10 aut.</sZ><sZ>11 aut.</sZ><sZ>12 aut.</sZ></fA14><fA20><s1>591-597</s1></fA20><fA21><s1>2012</s1></fA21><fA23 i1="01"><s0>ENG</s0></fA23><fA43 i1="01"><s1>INIST</s1><s2>19903</s2><s5>354000509770090290</s5></fA43><fA44><s0>0000</s0><s1>© 2012 INIST-CNRS. All rights reserved.</s1></fA44><fA45><s0>18 ref.</s0></fA45><fA47 i1="01" i2="1"><s0>12-0182435</s0></fA47><fA60><s1>P</s1></fA60><fA61><s0>A</s0></fA61><fA64 i1="01" i2="1"><s0>European journal of clinical microbiology & infectious diseases : (Print)</s0></fA64><fA66 i1="01"><s0>DEU</s0></fA66><fC01 i1="01" l="ENG"><s0>We aimed to assess the immunogenicity of a single half-dose of AS03-adjuvanted monovalent 2009 pandemic H1N1 vaccine in healthy adults. Healthy subjects age 20-60 years were prospectively enrolled in a cohort receiving intramuscular administration of a single half-dose (1.875 μg of hemagglutinin [HA]) of adjuvanted 2009 pandemic H1N1 influenza vaccine. Data from participants enrolled in a concomitant study of immunogenicity following a full-dose (3.75 μg of HA) are presented concurrently. Sera for assessment of hemagglutination-inhibiting (HAI) antibody to the vaccine strain were obtained before and 14 or 21 days after vaccination. Ninety-seven participants received a half-dose and 50 received a full-dose of vaccine. In the half-dose cohort, Food and Drug Administration criteria for immunogenicity regarding seroprotection and seroconversion rates were met for subjects aged 20-45 years, but not for those aged 46-60 years. There was no statistically significant difference in the proportion of individuals achieving a post-vaccination HAI titre of ≥1:40, the geometric mean titres of post-vaccination antibody, or the proportion of individuals with a four-fold or greater increase in antibody levels between the two cohorts. Participants 46-60 years of age were significantly less likely to be seroprotected at day 21 than those 20-45 years old in both cohorts. Immunogenicity of a half dose of adjuvanted pH1N1 influenza vaccine was adequate in subjects aged 20-45 years. Dose reduction is a possible strategy for expanding the availability in the event of vaccine shortage in this age group.</s0></fC01><fC02 i1="01" i2="X"><s0>002B05C02C</s0></fC02><fC03 i1="01" i2="X" l="FRE"><s0>Grippe A</s0><s5>01</s5></fC03><fC03 i1="01" i2="X" l="ENG"><s0>Influenza A</s0><s5>01</s5></fC03><fC03 i1="01" i2="X" l="SPA"><s0>Gripe A</s0><s5>01</s5></fC03><fC03 i1="02" i2="X" l="FRE"><s0>Immunoprophylaxie</s0><s5>04</s5></fC03><fC03 i1="02" i2="X" l="ENG"><s0>Immunoprophylaxis</s0><s5>04</s5></fC03><fC03 i1="02" i2="X" l="SPA"><s0>Inmunoprofilaxia</s0><s5>04</s5></fC03><fC03 i1="03" i2="X" l="FRE"><s0>Immunogénicité</s0><s5>07</s5></fC03><fC03 i1="03" i2="X" l="ENG"><s0>Immunogenicity</s0><s5>07</s5></fC03><fC03 i1="03" i2="X" l="SPA"><s0>Inmunogenicidad</s0><s5>07</s5></fC03><fC03 i1="04" i2="X" l="FRE"><s0>Dose</s0><s5>08</s5></fC03><fC03 i1="04" i2="X" l="ENG"><s0>Dose</s0><s5>08</s5></fC03><fC03 i1="04" i2="X" l="SPA"><s0>Dosis</s0><s5>08</s5></fC03><fC03 i1="05" i2="X" l="FRE"><s0>Prévention</s0><s5>09</s5></fC03><fC03 i1="05" i2="X" l="ENG"><s0>Prevention</s0><s5>09</s5></fC03><fC03 i1="05" i2="X" l="SPA"><s0>Prevención</s0><s5>09</s5></fC03><fC03 i1="06" i2="X" l="FRE"><s0>Vaccin</s0><s5>13</s5></fC03><fC03 i1="06" i2="X" l="ENG"><s0>Vaccine</s0><s5>13</s5></fC03><fC03 i1="06" i2="X" l="SPA"><s0>Vacuna</s0><s5>13</s5></fC03><fC03 i1="07" i2="X" l="FRE"><s0>Adulte</s0><s5>14</s5></fC03><fC03 i1="07" i2="X" l="ENG"><s0>Adult</s0><s5>14</s5></fC03><fC03 i1="07" i2="X" l="SPA"><s0>Adulto</s0><s5>14</s5></fC03><fC03 i1="08" i2="X" l="FRE"><s0>Etude cohorte</s0><s5>15</s5></fC03><fC03 i1="08" i2="X" l="ENG"><s0>Cohort study</s0><s5>15</s5></fC03><fC03 i1="08" i2="X" l="SPA"><s0>Estudio cohorte</s0><s5>15</s5></fC03><fC03 i1="09" i2="X" l="FRE"><s0>Microbiologie</s0><s5>17</s5></fC03><fC03 i1="09" i2="X" l="ENG"><s0>Microbiology</s0><s5>17</s5></fC03><fC03 i1="09" i2="X" l="SPA"><s0>Microbiología</s0><s5>17</s5></fC03><fC03 i1="10" i2="X" l="FRE"><s0>Grippe H1N1</s0><s4>CD</s4><s5>96</s5></fC03><fC03 i1="10" i2="X" l="ENG"><s0>H1N1 influenza</s0><s4>CD</s4><s5>96</s5></fC03><fC03 i1="10" i2="X" l="SPA"><s0>Gripe H1N1</s0><s4>CD</s4><s5>96</s5></fC03><fC07 i1="01" i2="X" l="FRE"><s0>Virose</s0></fC07><fC07 i1="01" i2="X" l="ENG"><s0>Viral disease</s0></fC07><fC07 i1="01" i2="X" l="SPA"><s0>Virosis</s0></fC07><fC07 i1="02" i2="X" l="FRE"><s0>Infection</s0></fC07><fC07 i1="02" i2="X" l="ENG"><s0>Infection</s0></fC07><fC07 i1="02" i2="X" l="SPA"><s0>Infección</s0></fC07><fC07 i1="03" i2="X" l="FRE"><s0>Homme</s0></fC07><fC07 i1="03" i2="X" l="ENG"><s0>Human</s0></fC07><fC07 i1="03" i2="X" l="SPA"><s0>Hombre</s0></fC07><fC07 i1="04" i2="X" l="FRE"><s0>Pathologie de l'appareil respiratoire</s0><s5>37</s5></fC07><fC07 i1="04" i2="X" l="ENG"><s0>Respiratory disease</s0><s5>37</s5></fC07><fC07 i1="04" i2="X" l="SPA"><s0>Aparato respiratorio patología</s0><s5>37</s5></fC07><fN21><s1>135</s1></fN21><fN44 i1="01"><s1>OTO</s1></fN44><fN82><s1>OTO</s1></fN82></pA></standard></inist></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/PandemieGrippaleV1/Data/PascalFrancis/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001738 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Curation/biblio.hfd -nk 001738 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= PandemieGrippaleV1
|flux= PascalFrancis
|étape= Curation
|type= RBID
|clé= Pascal:12-0182435
|texte= Immunogenicity of a half-dose of adjuvanted 2009 pandemic H1N1 influenza vaccine in adults: a prospective cohort study
}}
| This area was generated with Dilib version V0.6.34. |  |